Health2 years ago
Long-term benefits of amibantamab continue in post-platinum NSCLC
Long-term data from the CHRYSALIS trial (NCT02609776) continued to demonstrate the clinical benefit of amivantamabvmjw (Rybrevant), according to study results presented at the European Lung Cancer...
Recent Comments